Google is about to take a step further into the dark side, by implementing a dark mode setting on its desktop search page. If there’s something we know for sure, it’s that people (and vampires) love dark mode so this will go down a storm with the search engine’s users (especially those who enjoy a late night Google). In case you’ve been living purely in the light up until now, dark mode is a setting that turns an app or homepage from its usual colour profile into, you’ve guessed it, a dark… Source link
Read More »Google is testing a dark mode for desktop search
Google is testing a dark mode for desktop search, Google confirmed to The Verge. If the test has rolled out to you and your system is set to dark mode, the background of Google’s search pages will be a very dark gray. Here’s an example of what the dark mode looks like: It’s unclear how widely the test has been rolled out. A couple of Verge staffers had their search pages automatically switch to dark mode, and
Read More »Google Calendar’s desktop site can work offline again, in some cases
TipRanks Are These 3 Electric Car Stocks Still Worth Buying? Analyst Weighs In Electric cars are growing in popularity, a trend fueled by social acceptance, the green mentality, and a recognition that the internal combustion engine does have its flaws. Some of those flaws are addressed by electric vehicles (EVs). They bring lower emissions, less pollution from the car, and the promise of high performance off the mark. For the present, the main drawbacks are the high cost and relatively short… Source link
Read More »Google is reportedly testing dark mode for desktop web searches – Yahoo Tech
Bloomberg AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push (Bloomberg) — AstraZeneca Plc, one of the drugmakers leading the fight against Covid-19, highlighted where its growth will come from after the pandemic with a $39 billion deal for rare-disease specialist Alexion Pharmaceuticals Inc.The proposed cash-and-stock acquisition will add treatments for uncommon blood and immunological disorders to the portfolio of Cambridge, U.K.-based AstraZeneca, which had spent years paring… Source link
Read More »